|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,816.50 GBX | -1.70% |
|
-3.69% | -0.44% |
| 01-16 | Where the Money's Moving |  |
| 01-16 | Some drugmakers quietly concerned about legal risk with speedy FDA review program | RE |
| Capitalization | 72.88B 97.55B 84.09B 78.29B 136B 8,851B 146B 901B 355B 4,222B 366B 358B 15,416B | P/E ratio 2025 * |
13.4x | P/E ratio 2026 * | 11.6x |
|---|---|---|---|---|---|
| Enterprise value | 87.01B 116B 100B 93.47B 162B 10,567B 174B 1,075B 424B 5,040B 437B 428B 18,405B | EV / Sales 2025 * |
2.68x | EV / Sales 2026 * | 2.49x |
| Free-Float |
94.52% | Yield 2025 * |
3.57% | Yield 2026 * | 3.84% |
Last Transcript: GSK plc
| 1 day | -1.70% | ||
| 1 week | -3.69% | ||
| Current month | -0.44% | ||
| 1 month | -0.93% | ||
| 3 months | +11.78% | ||
| 6 months | +28.56% | ||
| Current year | -0.44% |
| 1 week | 1,795 |  | 1,902.5 |
| 1 month | 1,793 | | 2,057.7 |
| Current year | 1,795 | | 1,909.73 |
| 1 year | 1,242.5 | | 2,057.7 |
| 3 years | 1,242.5 | | 2,057.7 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
Charles Bancroft
BRD | Director/Board Member | 66 | 01/05/2020 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +1.50% | 3.15% | 26 M€ | |
| +0.13% | 2.97% | 62 M€ | |
| +6.67% | 2.51% | 8 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.70% | -3.69% | +33.66% | +26.34% | 97.55B | |
| +0.53% | -2.37% | +43.09% | +190.27% | 930B | |
| -0.41% | +6.98% | +48.72% | +26.86% | 527B | |
| -0.31% | -2.60% | +24.94% | +40.25% | 379B | |
| +0.93% | +2.38% | +31.46% | +18.47% | 371B | |
| +0.19% | -1.15% | +28.47% | +21.14% | 292B | |
| +0.98% | +1.37% | +29.42% | +35.03% | 276B | |
| -1.93% | -1.54% | +11.14% | -1.47% | 270B | |
| +6.49% | +1.95% | -32.44% | -18.44% | 268B | |
| +0.12% | +1.32% | +21.43% | +22.64% | 178B | |
| Average | +0.49% | +0.26% | +23.99% | +36.11% | 358.85B | |
| Weighted average by Cap. | +0.53% | +0.39% | +29.17% | +64.17% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 32.5B 43.5B 37.5B 34.91B 60.51B 3,947B 65.1B 402B 158B 1,882B 163B 160B 6,874B | 34.04B 45.56B 39.28B 36.56B 63.38B 4,134B 68.19B 421B 166B 1,972B 171B 167B 7,200B |
| Net income | 5.31B 7.11B 6.13B 5.7B 9.89B 645B 10.64B 65.62B 25.87B 308B 26.66B 26.11B 1,123B | 6.32B 8.46B 7.29B 6.79B 11.77B 768B 12.66B 78.11B 30.8B 366B 31.73B 31.08B 1,337B |
| Net Debt | 14.13B 18.91B 16.31B 15.18B 26.31B 1,716B 28.31B 175B 68.85B 819B 70.93B 69.47B 2,989B | 11.71B 15.67B 13.51B 12.58B 21.8B 1,422B 23.46B 145B 57.05B 678B 58.77B 57.56B 2,477B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 1,816.50 p | -1.70% | 14,633,600 |
| 15/01/26 | 1,848.00 p | -1.73% | 4,981,120 |
| 14/01/26 | 1,880.50 p | +1.21% | 6,553,009 |
| 13/01/26 | 1,858.00 p | -1.01% | 5,789,940 |
| 12/01/26 | 1,877.00 p | -0.48% | 5,648,904 |
Delayed Quote London S.E., January 16, 2026 at 07:35 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition